Search
Viltolarsen
go.drugbank.com/drugs/DB15005ApprovedInvestigational[A218186, L15526] In this manner, PMOs are much less susceptible to endo- and exonucleases and exhibit drastically reduced metabolic degradation compared to traditional synthetic oligonucleotides. … [A218171, A218176, A218191] The application of antisense oligonucleotides in DMD patients with specific mutations allows for exon skipping, which retains a productive reading frame and results in the
Frovatriptan
go.drugbank.com/drugs/DB00998ApprovedFrovatriptan causes vasoconstriction of arteries and veins that supply blood to the head. … Frovatriptan is a triptan drug developed by Vernalis for the treatment of migraine headaches, in particular those associated with menstruation.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Receptor AgonistsBezitramide
go.drugbank.com/drugs/DB01459ApprovedIllicitWithdrawnAfter cases of fatal overdose in the Netherlands in 2004 the drug was withdrawn from the market. Bezitramide has never been FDA approved and is currently a schedule II drug. … Bezitramide is a narcotic analgesic which was discovered in 1961, clinically tested around the 1970's [A14383], and marketed under the name Burgodin.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeApazunersen
go.drugbank.com/drugs/DB16981InvestigationalApazunersen is an antisense oligonucleotide designed to target and inhibit the expression of UBE3A-AS. It is being investigated for the treatment of Angelman Syndrome.[L46772]
Categories: Antisense Oligonucleotide Specific to the Antisense Transcript of UBE3ATozinameran
go.drugbank.com/drugs/DB15696ApprovedInvestigational[L26966,L26976] In November 2021, Health Canada [L39115] and the EMA [L39272] approved the vaccine to be administered as a booster dose approximately six months after the second dose. … [L36025] Currently, sufficient data are not available to determine the longevity of protection against COVID-19, nor direct evidence that the vaccine prevents the transmission of the SARS-CoV-2 virus
Meradimate
go.drugbank.com/drugs/DB11096Approved[T200] It is currently required to be named as meradimate in all FDA approved OTC products. Meradimate is approved by the FDA and Health Canada to be used as an ingredient in sunblocking products.
Eph receptors
go.drugbank.com/bio_entities/BE0028186TargetHumansReceptor for members of the ephrin-A family. Binds to EFNA3, EFNA4 and EFNA5 … Cognate/functional ephrin ligands for this receptor include EFNB1, EFNB2 and EFNB3.
Polypeptides: Ephrin type-A receptor 1, Ephrin type-A receptor 10Synonyms: Tyrosine-protein kinase receptor EPH, Tyrosine-protein kinase receptor ECKAmantadine
go.drugbank.com/drugs/DB00915ApprovedInvestigationalAn antiviral that is used in the prophylactic or symptomatic treatment of influenza A. It is also used as an antiparkinsonian agent, to treat extrapyramidal reactions, and for postherpetic neuralgia. … The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.
Mixtures: ROSEL-TCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, NMDA Receptor AntagonistsFluoxetine
go.drugbank.com/drugs/DB00472ApprovedInvestigationalVet approved[A181673] It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Receptor AntagonistsProducts: FLUOXETIN-NEURAX 20 MG TAminopterin
go.drugbank.com/drugs/DB08878ApprovedWithdrawnClinicians need to be aware of the characteristic teratologic effects of aminopterin and methotrexate. … In the 1950's its production was discontinued in favor of methotrexate, which is less potent but less toxic. Off label, aminopterin has also been used in the treatment of psoriasis.